Skip to main content

Table 3 Distribution of absolute and percentage change in haemoglobin and risk of anaemia by the treatment group and G6PD status

From: The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis

 

Any G6PD status

Normal G6PD status

Unknown G6PD status

Day and metric

Chloroquine alone

Chloroquine plus primaquine

Chloroquine alone

Chloroquine plus primaquine

Chloroquine alone

Chloroquine plus primaquine

Day 2/3 (number of patients)

610*

471†

338

334

258

137

 Absolute change‡, mean (SD) [range]; g/dL

− 0.5 (1.1) [− 4.6 to 3.4]

− 1.1 (1.6) [− 6.4 to 5.0]

− 0.9 (1.2) [− 4.6 to 3.4]

− 1.2 (1.3) [−  4.2 to 5.0]

0.1 (0.6) [− 2.1 to 2.8]

− 1.0 (2.1) [− 6.4 to 3.8]

 Percentage change‡, mean (SD) [range]; %

− 3.5 (8.5) [− 32.3 to 34.3]

− 8.0 (11.8) [− 39.4 to 60.8]

− 6.7 (9.0) [− 32.3 to 34.3]

− 8.8 (10.1) [− 39.4 to 60.8]

0.9 (5.4) [− 17.1 to 27.5]

− 6.2 (14.9) [− 35.8 to 35.5]

 Percentage fall > 25%

7/610 (1.1%)

27/471 (5.7%)

7/338 (2.1%)

11/334 (3.3%)

0/258 (0%)

16/137 (11.7%)

 > 25% fall associated with severe anaemia (%)§

0/610 (0%)

1/471 (0.2%)

0/338 (0%)

1/334 (0.3%)

0/258 (0%)

0/137 (0%)

 Absolute fall > 5 g/dL¶

0/610 (0%)

6/471 (1.3%)

0/338 (0%)

0/334 (0%)

0/258 (0%)

6/137 (4.4%)

Day 7 ± 2

1222

539

608

389

588

150

 Absolute change‡, mean (SD) [range]; g/dL

− 0.1 (1.2) [− 5.6 to 6.5]

− 1.0 (1.6) [− 7.3 to 5.4]

− 0.2 (1.4) [− 4.6 to 6.5]

− 1.0 (1.5) [− 7.3 to 5.4]

0.1 (1.1) [− 5.6 to 5.4]

− 0.8 (2.0) [− 6.0 to 3.8]

 Percentage change‡, mean (SD) [range]; %

0.4 (10.5) [− 40.6 to 64.4]

− 6.5 (12.3) [− 55.3 to 65.5]

− 0.7 (11.3) [− 33.0 to 64.4]

− 7.3 (11.5) [− 55.3 to 65.5]

1.7 (9.4) [− 40.6 to 52.4]

− 6.2 (14.9) [− 35.8 to 35.5]

 Percentage fall > 25%

5/1222 (0.4%)

33/539 (6.1%)

4/608 (0.7%)

20/389 (5.1%)

1/588 (0.2%)

13/150 (8.7%)

 > 25% fall associated with severe anaemia (%)§

0/1220 (0%)

1/539 (0.2%)

0/608 (0%)

1/389 (0.3%)

0/586 (0%)

0/150 (0%)

Absolute fall > 5 g/dL¶

1/1222 (0.1%)

8/539 (1.5%)

0/608 (0%)

4/389 (1.0%)

1/588 (0.2%)

4/150 (2.7%)

Day 28 ± 3

1579

917

731

472

826

444

 Absolute change‡, mean (SD) [range]; g/dL

0.5 (1.4) [− 6.9 to 6.2]

0.4 (1.7) [− 6.8 to 6.7]

0.4 (1.5) [− 4.7 to 6.2]

0.4 (1.4) [− 4.2 to 6.2]

0.5 (1.4) [− 6.9 to 6.0]

0.5 (1.9) [− 6.8 to 6.7]

 Percentage change‡, mean (SD) [range]; %

5.0 (13.4) [− 46.3 to 81.7]

5.1 (16.5) [− 51.1 to 136.7]

4.2 (13.1) [− 39.5 to 74.7]

4.2 (12.8) [− 36.2 to 74.8]

5.8 (13.7) [− 46.3 to 81.7]

6.1 (19.7) [− 51.1 to 136.7]

 Percentage fall > 25%

9/1579 (0.6%)

13/917 (1.4%)

6/731 (0.8%)

2/472 (0.4%)

3/826 (0.4%)

11/444 (2.5%)

 > 25% fall associated with severe anaemia (%)§

1/1576 (0.1%)

3/906 (0.3%)

0/730 (0%)

0/472 (0%)

1/824 (0.1%)

3/433 (0.7%)

 Absolute fall > 5 g/dL¶

1/1579 (0.1%)

3/917 (0.3%)

0/731 (0%)

0/472 (0%)

1/826 (0.1%)

3/444 (0.7%)

  1. CI confidence interval, Hb haemoglobin, No number, SD standard deviation
  2. *Includes 338 patients with normal G6PD status, 258 with unknown status and 14 with borderline or deficient status
  3. †Includes 334 patients with normal G6PD status and 137 with unknown status
  4. ‡Results are reported as a change in haemoglobin, with positive results reflecting a rise in Hb and negative results reflecting a fall in Hb
  5. §Patients were considered to develop severe anaemia if their baseline Hb was ≥ 7 g/dL and their follow-up Hb was < 7 g/dL, with the denominator the number of people with a Hb recorded for that day who had a baseline ≥ 7 g/dL. All patients that developed severe anaemia had a Hb fall > 25%. Additional file 1: Table S12 provides additional patient details
  6. ¶Additional file 1: Table S13 provides additional patient details